Ionis Pharmaceuticals Inc
IONS
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.4B
Close$
$-57.64
201.9% downside
Current Fair Value
201.9% downsideOvervalued by 201.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.40 Billion |
|---|---|
| Enterprise Value | $9.77 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.37 |
| Outstanding Shares | 165,419,000 |
Return
| Return on Equity | -48.16% |
|---|---|
| Return on Assets | -7.07% |
| Return on Invested Capital | -7.85% |
Valuation & Multiples
| P/E Ratio | -16.35 |
|---|---|
| PEG | 8.49 |
| Price to Sales | 9.43 |
| Price to Book Ratio | 28.28 |
| Enterprise Value to Revenue | 8.7 |
| Enterprise Value to EBIT | -46.42 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 5.51 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
$187.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$183.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 102.28% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.61%▼ 105.26% |
|---|---|
| Total Invested | $339.38M▼ 97.38% |
| Investors Holding | 130▼ 393.00% |
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...